Beyond classical TCD-haplo, ATIR101 could even be a beneficial adjunctive to alpha–beta T-cell-CD19-depleted haploidentical HSCT, providing additional graft-versus-infection and -leukemia effects to the immunity of NK cells and gamma–delta T cells [21, 22, 60–62]. The gene discussed is CD19; the disease is leukemia.